Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF-mutant melanoma

被引：3
|
作者：
Schadendorf, Dirk
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Mortier, Laurent
Robert, Caroline
Schachter, Jacob
Ji, Ran
Aimone, Paola
Manson, Stephanie
Kefford, Richard
Dummer, Reinhard
Kirkwood, John M.
Long, Georgina V.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Fdn Ist Nazl Tumori, Milan, Italy
[4] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Brisbane, Qld 4072, Australia
[5] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy
[6] Veneto Oncol Inst, Melanoma Oncol Unit, Padua, Italy
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Oslo Univ Hosp, Norwegian Radium Hosp, Oslo, Norway
[9] Ctr Hosp Univ Bordeaux, Hop St Andre, Bordeaux, France
[10] Alfred Hosp, Melbourne, Australia
[11] Univ Lille, INSERM, U 1189, Lille, France
[12] Inst Gustave Roussy, Paris, France
[13] Sheba Med Ctr, Ella Inst Melanoma, Tel Hashomer, Israel
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Novartis AG, Basel, Switzerland
[16] Macquarie Univ, Melanoma Inst Australia, Westmead Hosp, Sydney, NSW, Australia
[17] Univ Sydney, Sydney, NSW, Australia
[18] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland
[19] Univ Pittsburgh, Melanoma Program, Hillman UPMC Canc Ctr, Pittsburgh, PA USA
[20] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia
[21] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9590
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dabrafenib plus trametinib (D plus T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification
    Larkin, James M. G.
    Hauschild, Axel
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Chiarion-Sileni, Vanna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma
    Hauschild, A.
    Santinami, M.
    Long, G. V.
    Atkinson, V.
    Mandala, M.
    Sileni, V. Chiarion
    Nyakas, M. S.
    Dutriaux, C.
    Haydon, A.
    Robert, C.
    Mortier, L.
    Schachter, J.
    Ji, R.
    Zhang, P.
    Mookerjee, B.
    Legos, J.
    Kefford, R.
    Dummer, R.
    Kirkwood, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Long-term benefit of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF V600-mutant melanoma: Five-year analysis of COMBI-AD.
    Hauschild, Axel
    Dummer, Reinhard
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Kirkwood, John M.
    Sileni, Vanna Chiarion
    Larkin, James M. G.
    Nyakas, Marta
    Dutriaux, Caroline
    Haydon, Andrew Mark
    Robert, Caroline
    Mortier, Laurent
    Schachter, Jacob
    Dasgupta, Kohinoor
    Gasal, Eduard
    Tan, Monique
    Long, Georgina V.
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
    Long, G. V.
    Hauschild, A.
    Santinami, M.
    Atkinson, V. G.
    Mandala, M.
    Chiarion-Sileni, V.
    Larkin, J.
    Robert, C.
    Schadendorf, D.
    Dasgupta, K.
    Shilkrut, M.
    Garrett, J.
    Brase, J. C.
    Kefford, R.
    Kirkwood, J. M.
    Dummer, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600-mutant melanoma
    Grob, J. J.
    Robert, C.
    Long, G. V.
    Stroyakovskiy, D.
    Levchenko, E.
    Chiarion-Sileni, V.
    Flaherty, K.
    Nathan, P.
    Ribas, A.
    Davies, M.
    Zhang, J.
    Chen, L.
    Mookerjee, B.
    Redhu, S.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D plus T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)
    Grob, J. J.
    Amonkar, M.
    Karaszewska, B.
    Schachter, J.
    Dummer, R.
    Mackiewicz, A.
    Stroiakovski, D.
    Drucis, K.
    Grange, F.
    Chiarion-Sileni, V.
    Rutkowski, P.
    Lichinitser, M.
    Levchenko, E.
    Wolter, P.
    Hauschild, A.
    Long, G. V.
    Sun, P.
    McDowell, D. O.
    Mookerjee, B.
    Robert, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S682 - S683
  • [7] Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
    Wilmott, James S.
    Tawbi, Hussein
    Engh, Johnathan A.
    Amankulor, Nduka M.
    Shivalingam, Brindha
    Banerjee, Hiya
    Vergara, Ismael A.
    Lee, Hansol
    Johansson, Peter A.
    Ferguson, Peter M.
    Saiag, Philippe
    Robert, Caroline
    Grob, Jean -Jacques
    Butterfied, Lisa H.
    Scolyer, Richard A.
    Kirkwood, John M.
    V. Long, Georgina
    Davies, Michael A.
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 521 - 531
  • [8] COST PER OUTCOME ANALYSIS OF NIVOLUMAB VERSUS DABRAFENIB plus TRAMETINIB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE IIIB/C BRAF-MUTANT CUTANEOUS MELANOMA IN SPAIN
    Sanchez, Polanco C.
    Moshyk, A.
    Amadi, A.
    Poretta, T.
    Galan, J.
    Vembusubramanian, M.
    Betts, K. A.
    Du, E. X.
    VALUE IN HEALTH, 2020, 23 : S445 - S445
  • [9] Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) plus trametinib (T) or placebo (PBO).
    Schadendorf, Dirk
    Dummer, Reinhard
    Hauschild, Axel
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Chiarion-Sileni, Vanna
    Larkin, James M. G.
    Nyakas, Marta
    Dutriaux, Caroline
    Haydon, Andrew Mark
    Mortier, Laurent
    Robert, Caroline
    Schachter, Jacob
    Ortmann, Christine-Elke
    De Jong, Egbert
    Gasal, Eduard
    Kefford, Richard
    Kirkwood, John M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Adjuvant Therapy Using Dabrafenib plus Trametinib in Chinese Patients with Resected Stage III Melanoma: A Multicenter Retrospective Cohort Study
    Jia, Dong-Dong
    Xu, Yu
    Li, Ting
    Yang, Ji-Long
    Chen, Yong
    Li, Tao
    DERMATOLOGIC THERAPY, 2024, 2024
12345